


MP38-7 The effect of beta-3 adrenergic receptor agonist on micromotions of major pelvic ganglion disconnected rat bladder

Hee Seo Son, Soo Young Moon, Hyun Kyu Ahn, Kyung Taek Oh, Jee Soo Park, Jee Soo Ha, and Jang Hwan Kim*

From the Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea



Background

◆ What is Micromotion

Micromotion is intrinsic localized motility of bladder wall, comprising microcontractions and microelongations

◆ How is Micromotion generated

Micromotion is regarded to be associated with disinhibited autonomy expressed when normal descending inhibitory influences are lost

◆ Can we detect micromotion with CMG

Increased coordination of micromotion waves may be expressed as intravesical phasic pressure fluctuations in case of altered neural modulation

◆ Why is micromotion important

Local distortion of bladder wall made by autonomous micromotions may generate afferent nerve activity resulting in increased filling sensation, urgency, or pelvic pain

◆ Can we modulate micromotion

β3-adrenoceptor agonists showed effectiveness in inhibiting mechanosensitive bladder afferent activity, which may be related to suppression of bladder microcontractions

◆ Subjects to be elucidated for clinical application

For effective management of patients with defect in neural pathway, proper therapeutic target should be defined, and the followings are to be clarified

- ✓ The site responsible for initiation and/or propagation of micromotions
- ✓ The effect of β3-adrenoceptor agonists on micromotion in living animal
- ✓ The action site of β3-adrenoceptor agonists

Objectives

To evaluate the effect of beta-3 adrenergic receptor agonist on micromotions of major pelvic ganglion disconnected rat bladder

Methods

◆ Animals

Male Sprague-Dawley rats (N=18)

◆ Disconnection of major pelvic ganglion

Rats were anesthetized with 2% isoflurane in oxygen. MPGs were identified in the lateral aspect of the prostate and were carefully removed under microscope



Experiments were performed after 1 week of adaptation period following MPG disconnection

◆ Grouping of subject animals

1. β3 adrenergic receptor agonist (CL-316243) group
2. β3 adrenergic receptor antagonist (SR59230A) pretreated CL-316243 group
3. Non-selective muscarinic receptor antagonist (Oxybutynin) group

◆ Cystometogram

PE-50 tubing was introduced into in the bladder and cystometry was performed by infusing physiological saline at a rate of 0.12ml/min

◆ Assessment

Frequency of micromotion was checked at baseline, after administration of vehicle (saline) (i.a.), after administration of each target agent (i.a.) consecutively

Results

- ◆ Micromotion frequency was significantly decreased after injection of CL-316243 ($2.2 \pm 3.5/10\text{min}$) compared to baseline ($7.5 \pm 2.6/10\text{min}$) ($P=0.005$)
- ◆ There was no significant change of micromotion frequency in SR59230A pretreated CL-316243 group ($6.3 \pm 2.9/10\text{min}$) compared to baseline ($6.3 \pm 0.5/10\text{min}$) ($P=1.000$)
- ◆ The number of micromotion after Oxybutynin injection ($3.2 \pm 3.1/10\text{min}$) was not significantly different from that of baseline ($5.7 \pm 3.1/10\text{min}$) ($P=0.059$)




Figure 1. Representative recording of micromotion, (A) The frequency of micromotion was significantly decreased after intra-arterial administration of beta-3 adrenergic receptor agonist (CL-316243) (0.5mg/kg), (B) The frequency of micromotion was not significantly decreased after intra-arterial administration of Oxybutynin (0.5mg/kg). However after administration of the beta-3 adrenergic receptor agonist (CL-316243) (0.5mg/kg), noticeable decrease in frequency of micromotion was observed




Figure 2. Frequency change of micromotion of each group (mean number per 10 minutes) (A) CL-316243 group (n=6) (B) SR59230A pretreated CL-316243 group (n=6), (C) Oxybutynin group (n=6), **, significant at $P<0.01$

References

1. *Acta Physiol (Oxf)* 2015;213:360-70
2. *The Journal of urology*. 2003;170:276-9
3. *BJU international*. 2005;95:1002-5. *Int Urogynecol J* (2001) 12:89-96
4. *European urology*. 2012;62:1165-73
5. *Naunyn-Schmiedeberg's archives of pharmacology*. 2015;388:695-708.
6. *BJU international*. 2017;119:22-9
7. *Nature reviews Urology*. 2017;14:330-2
8. *Autonomic neuroscience : basic & clinical*. 2016;198:33-7.

Conclusions

- ◆ We could observe that systemically administrated beta-3 adrenergic receptor agonist have effect in alleviating micromotions of MPG disconnected rat bladder
- ◆ These results also suggest that beta-3 adrenergic receptor agonist might be an effective agent in controlling the initiation of overactive bladder